Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±-5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.

被引：0
|
作者：
Macarulla, Teresa Mercade
Hubner, Richard
Blanc, Jean-Frederic
Wang-Gillam, Andrea
Li, Chung-Pin
Bodoky, Gyorgy
Dean, Andrew Peter
Yanshen, Shan
Jameson, Gayle S.
Lee, Kyung-Hun
Chiu, Chang-Fang
Schwartsmann, Gilberto
Braiteh, Fadi S.
Cunningham, David
Chen, Li-Tzong
Von Hoff, Daniel D.
Mamlouk, Khalid Kevin
de Jong, Floris A.
Siveke, Jens T.
机构：
[1] Vall d Hebron Univ Hosp, Inst Oncol, Barcelona, Spain
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] CHU Bordeaux, Pole ADEN, Hop Haut Leveque, Bordeaux, France
[4] Washington Univ, Sch Med St Louis, St Louis, MO USA
[5] Taipei Vet Gen Hosp, Taipei, Taiwan
[6] Szent Laszlo Teaching Hosp, Budapest, Hungary
[7] St John God Hosp, Subiaco, WA, Australia
[8] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[9] Honor Hlth, Virginia G Piper Canc Ctr, Scottsdale, AZ USA
[10] Seoul Natl Univ Hosp, Seoul, South Korea
[11] China Med Univ First Hosp, Taichung, Taiwan
[12] Fed Univ, Porto Alegre, RS, Brazil
[13] Comprehens Canc Centers Nevada, Las Vegas, NV USA
[14] Royal Marsden NHS Fdn Trust, London, England
[15] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan
[16] Ipsen Biosci Inc, Cambridge, MA USA
[17] Shire GmbH, Zug, Switzerland
[18] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.410
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
410
引用
收藏
页数：1
相关论文
共 49 条
  • [1] A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Siveke, Jens T.
    Hubner, Richard
    Macarulla, Teresa Mercade
    Wang-Gillam, Andrea
    Dean, Andrew Peter
    Blanc, Jean-Frederic
    Cunningham, David
    Mirakhur, Beloo
    Belanger, Bruce
    de Jong, Floris A.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris A.
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [4] Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Macarulla, Teresa Mercade
    Siveke, Jens T.
    Dean, Andrew Peter
    Hubner, Richard
    Blanc, Jean-Frederic
    Cunningham, David
    Chen, Li-Tzong
    Mirakhur, Beloo
    Chen, Jie
    de Jong, Floris A.
    Wang-Gillam, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] Subgroup analysis by prior lines of metastatic therapy (mtx) in NAPOLI-1: A global, randomized phase 3 study of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV), vs. 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed following gemcitabine-based therapy.
    Bodoky
    Dean, Andrew Peter
    Yanshen, Shan
    Jameson, Gayle S.
    Lee, Kyung-Hun
    Blanc, Jean-Frederic
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Braiteh, Fadi S.
    Cunningham, David
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    Mamlouk, Khalid Kevin
    Bhargava, Parul
    de Jong, Floris A.
    Hubner, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
    Chen, L-T.
    Macarulla Mercade, T.
    Lee, K-H.
    Lakatos, G.
    Wang-Gillam, A.
    Mirakhur, B.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPOLI-1 trial
    Chen, Li-Tzong
    Wang-Gillam, Andrea
    Yanshen, Shan
    Macarulla, Teresa
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Pipas, J. Marc
    Belanger, Bruce
    de Jong, Floris
    Mamlouk, Khalid
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [8] Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).
    Im, Hyeon-Su
    Kim, Kyu-Pyo
    Oh, Do-Youn
    Lee, Kyung-Hun
    Chon, Hong Jae
    Kim, Joo Hoon
    Kang, Myoung Joo
    Kim, Il-Hwan
    Lee, Guk Jin
    Oh, Sung Yong
    Choi, Younak
    Choi, Hye Jin
    Kim, Seung Tae
    Park, Joon Oh
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [9] CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) 6 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Chen, L-T.
    Wang-Gillam, A.
    Shan, Y-S.
    Mercade, T. Macarulla
    Blanc, J. F.
    Hubner, R.
    Chiu, C-F.
    Schwartsmann, G.
    Siveke, J.
    Belanger, B.
    de Jong, F.
    Mamlouk, K.
    von Hoff, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI ±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
    Jean-Frederic, Blanc
    Richard, Hubner
    Li Chung-Pin
    Andrea, Wang-Gillam
    Gyorgy, Bodoky
    Andrew, Dean
    Shan Yan-Shen
    Gayle, Jameson
    Teresa, Macarulla
    Kyung-Hun, Lee
    David, Cunningham
    Chiu Chang-Fang
    Gilberto, Schwartsmann
    Fadi, Braiteh
    Daniel, Von Hoff
    Chen Li-Tzong
    Khalid, Mamlouk
    Parul, Bhargava
    Floris, de Jong
    Jens, Siveke
    ANNALS OF ONCOLOGY, 2017, 28
12345